一个多功能Ru-Re复合体用于光动力疗法和CO介导治疗在阿尔茨海默病的治疗方法
Chun Hau Gan1, Hsin-Jou Chen1, Ricky Yu-Syun Fan1
1Department of Chemistry, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd., Taipei, 10617, Taiwan.
Chemistry (Weinheim an der Bergstrasse, Germany)
|December 23, 2024
概括
一种新型的-复合物通过结合光动力疗法和一氧化碳释放来为阿尔茨海默病提供了双重治疗方法,显示出抑制陶聚合和改善线粒体功能的潜力.
科学领域:
- 无机化学 无机化学
- 药用化学 医学化学
- 神经科学是一个神经科学.
背景情况:
- 开发多功能药剂是治疗阿尔茨海默氏症等复杂疾病的关键.
- 目前的阿尔茨海默氏症治疗有局限性,需要新的治疗策略.
研究的目的:
- 设计和表征一种- (Ru-Re) 复合体,具有联合光动力学疗法 (PDT) 和一氧化碳 (CO) 释放能力.
- 评估这种Ru-Re复合物的阿尔茨海默病治疗潜力.
主要方法:
- 卢-雷复合物的合成和表征.
- 光物理研究评估单点氧 (1O2) 生产.
- 在体外测试评估CO释放,聚抑制和对线粒体呼吸的影响.
主要成果:
- Ru-Re复合体在辐射后证明了有效的1O2和CO生成.
- 该复合物在实验模型中成功抑制了tau聚合.
- 观察到线粒体呼吸的显著增强.
结论:
- 鲁-雷综合体展示了阿尔茨海默病的有希望的多功能治疗特性.
- 这种药物具有联合PDT和CO释放疗法的潜力,解决阿尔茨海默病的关键病理特征.
相关概念视频
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Electron Transport Chain: Complex I and II
11.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.3K
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444


